Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.
about
Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen MoleculesProtein Crystallography in Vaccine Research and DevelopmentThe effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccinationComplement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens.Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
P2860
Q27675010-9758F3B4-5C02-46D0-AD2A-89744416A658Q28087528-05413A76-3BA3-4D02-B25E-4974877A7DC1Q34270429-0D68AE64-DE5F-4F0F-853B-1859FC2B8065Q34594327-E0F548B2-F66C-41D7-BEAD-554D97E9F2CDQ34993283-BF08CDB2-AA2C-484D-88CE-879517A8C0D4Q35191862-8F3DB002-2797-41D9-8E26-57281155712AQ35658277-85D61ED1-9620-43F3-B667-1FBAD44E5FDCQ35965207-AB9D4403-F7E7-45A1-9C27-7617B3CAC43FQ36211092-8D932A80-DEFF-40A0-A059-60DA7DD1AE23Q36354851-DE5D740B-FA89-42EB-909A-31C94E72E0DDQ37002310-00024C15-159B-4772-BB58-57FA5F5FA6F6Q37163679-46A0E0C8-1A9C-4B40-8C5A-79DBB0F59888Q37277250-1622EAC5-4318-40C8-96BA-B15FD07F9635Q37798011-74023CE2-514E-4203-BCC4-026CD091BA71
P2860
Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@ast
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@en
type
label
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@ast
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@en
prefLabel
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@ast
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@en
P2093
P2860
P356
P1476
Impaired immunogenicity of a m ...... to eliminate factor h binding.
@en
P2093
Dan M Granoff
Jutamas Shaughnessy
Peter T Beernink
Sanjay Ram
P2860
P304
P356
10.1128/CVI.00103-10
P577
2010-06-02T00:00:00Z